Abiomed Inc.

NASDAQ:ABMD  
245.66
-3.30 (-1.33%)
Products

FDA Approves Recover IV Randomized Controlled Trial With Exception From Informed Consent

Published: 09/16/2022 12:15 GMT
Abiomed Inc. (ABMD) - FDA Approves Recover Iv Randomized Controlled Trial With Exception From Informed Consent (efic).
Abiomed Inc - FDA Approves Recover Iv Randomized Controlled Trial With Exception From Informed Consent.
Abiomed Inc - FDA Also Approves and Closes Recover Iii Post-approval Study.